A growing population, increased life expectancy and a willingness of its people to pay out-of-pocket for expensive drugs means the pharmaceutical market in Malaysia could grow by double-digits to 2020, according to a new report from research firm Frost & Sullivan. Released earlier this month, the report said companies should see "significant revenue-generating opportunities" and the country is emerging as a "hot favorite" for investors. The report highlights the government's "flexible regulatory landscape" for the drug market, but notes that international players looking to enter the country will likely have to partner with local companies because current regulations favor local firms. The country is also a favorite because of its reputation as a leading exporter of "halal" ingredients that are required in Muslim countries. Report